top of page
Science Lab

Colorectal Cancer Screening

Universal Diagnostics has developed an investigational blood-based test for colorectal cancer which is able to detect both pre-cancerous polyps and early stages of colorectal cancer.  An investigational test is one that is not approved by the U.S. Food and Drug Administration (FDA). This test uses a blood sample otherwise known as a “liquid biopsy”.  It is minimally invasive, quick, and is designed to assist doctors to detect, treat and monitor cancer in real-time. 

 

This study is evaluating Universal Diagnostic’s blood-based test called Signal-Cä. It uses biomarkers in your blood for the detection of colorectal cancer and pre-cancerous lesions

 

Purpose

​

The purpose of this study is to collect blood samples that can be used to test this device.  You will not receive any results from the study device.

​

Compensation

​

Up to $150

Are you eligible to participate? 

​

  • 45-84 years of Age

  • Intended to undergo a standard-of-care screening colonoscopy

  • Considered by a physician or healthcare provider as being of 'average risk' for CRC

  • Willing to consent to blood draw prior to bowel preparation and undergoing colonoscopy ideally within 90 days of the date of the investigational blood draw

  • Willing to consent to a follow-up phone call after one year

  • Able and willing to sign informed consent

bottom of page